Last reviewed · How we verify

NCT04232358

Resistance Training and Injection Treatment for Achilles Enthesopathy

Active, enrolled NA Last updated 12 August 2024
What this trial tests

NA trial testing Corticosteroid injection in Achilles Entesopathy in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 May 2021
Primary endpoint
4 November 2024
4 May 2025

Quick facts

Lead sponsorBispebjerg Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date4 May 2021
Primary completion4 November 2024
Estimated completion4 May 2025
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Bispebjerg Hospital

Who can join

Adults 18 to 65, any sex, with Achilles Entesopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Achilles enthesopathy is a common and often long-lasting injury among exercising individuals. Very little is known regarding the effect of different treatment strategies. The purpose of the study is to evaluate two treatment strategies for achilles enthesopathy: Resistance training and restricted loading + corticosteroid injection compared to resistance training and restricted loading + local anesthesia injection. 50 patients with achilles enthesopathy are randomly assigned to the two treatment groups in this double blinded RCT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Corticosteroid injection

Trials testing the same drug.

Other Bispebjerg Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing